Drugs & Targets FDA approves Enhertu in HER2+ early breast cancer for both neoadjuvant and adjuvant treatment May 22, 2026Vol.52 No.20
Drugs & Targets FDA approves Signatera CDx as a companion diagnostic in muscle-invasive bladder cancer May 22, 2026Vol.52 No.20
Drugs & Targets FDA grants priority review to Hyrnuo in first-line HER2-mutated NSCLC May 22, 2026Vol.52 No.20
Drugs & Targets FDA approves oral combination Inqovi plus venetoclax for newly diagnosed AML May 15, 2026Vol.52 No.19
Drugs & Targets Bizengri gets FDA approval for bile cancer, becomes seventh drug approved under the priority voucher program May 15, 2026Vol.52 No.19
Drugs & Targets FDA clears AI digital pathology risk stratification tool in breast cancer May 15, 2026Vol.52 No.19
Drugs & Targets FDA permits expanded access for investigational pancreatic cancer drug daraxonrasib May 08, 2026Vol.52 No.18By Claire Marie Porter
Drugs & Targets FDA approves Jakafi XR tablets for myelofibrosis, polycythemia vera, and graft-versus-host disease May 08, 2026Vol.52 No.18
